• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Lifeward launches next-gen ReWalk 7 personal exoskeleton in the US

Lifeward launches next-gen ReWalk 7 personal exoskeleton in the US

April 15, 2025 By Sean Whooley

Lifeward ReWalk 7 next-generation personal exoskeleton
The ReWalk 7 next-generation personal exoskeleton. [Image courtesy of Lifeward]
Lifeward (Nasdaq:LFWD) announced today that it launched the next-generation ReWalk 7 personal exoskeleton in the United States.

The company (formerly ReWalk Robotics) now plans to begin sales of the new, enhanced system in the U.S. Lifeward said it made the system available for personal use and in the clinical setting. It received FDA 510(k) clearance for the seventh-generation system last month.

ReWalk 7 includes a number of new features, enhancements and upgrades to provide a more functional and personalized walking experience for individuals with spinal cord injury (SCI). Those include cloud connectivity and customizable walking speeds for users.

According to the company, the new exoskeleton features smoother movement and seamless transitions between indoor and outdoor environments. A Crutch Control feature enables more control for the user, as they can stand, walk, select speeds and stop by touching a single button. New Wrist Control via smartwatch and the MyReWalk mobile app make it easier for users to select operation modes, set goals and track usage, too.

Lifeward says the new system allows users to walk longer and more often with an improved battery and seamless activation of stairs and curbs. Additionally, the all-new therapist handheld device and click-to-stop control enables safer, more effective progression to optimal gait patterns.

The latest milestone follows a series of positive steps for Lifeward following its 2024 rebrand to “Lifeward” to expand its portfolio. Larry Jasinski, CEO of Lifeward, spoke to MassDevice last year about the benefits of the rebrand.

Last year, the company hit milestones, including a national reimbursement policy from CMS, which followed 2023 clearance for the ReWalk 6.0 system for use on stairs and curbs.

Said Jasinski:

“The ReWalk 7 was developed over several years, integrating advanced technological innovations with  feedback from clinicians and patients to build upon the ReWalk’s world-class reputation for industry  leadership. The result is a device that is optimized for real-world  use, with an unmatched user experience and freedom of movement. We are thrilled to be able to  provide paralyzed individuals across the country with a new option for integrating walking to everyday  life.” 

Filed Under: Business/Financial News, Featured, Orthopedics, Prosthetics, Robotic-Assisted Tagged With: Lifeward, ReWalk Robotics

More recent news

  • Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
  • Autonomix taps former Medtronic FDA counsel head for board of directors
  • Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say
  • Science Corp. names president as it looks to roll out vision-restoring implant
  • Mindray looks to fill hospital ventilator gap left by Philips’ exit

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy